Michelle L. Ernst

Michelle’s experience includes:

• Amgen v. MSN – Represents Amgen in Hatch-Waxman patent litigation concerning Amgen’s Parsabiv® product
• Allele v. Regeneron – Represents Regeneron in patent litigation concerning its COVID-19 antibody, REGEN-COV®️
• Eli Lilly v. MSN – Represents Eli Lilly in Hatch-Waxman patent litigation concerning Lilly’s Olumiant® product
• Sebela v. Prinston – Represented Sebela in Hatch-Waxman patent litigation concerning Sebela’s Brisdelle® product
• Biogen v. Teva – Represented Biogen in Hatch-Waxman patent litigation concerning Biogen’s Vumerity® product
• Cephalon & Eagle Pharmaceuticals v. Slayback Pharma – Represented Eagle in Hatch-Waxman patent litigation concerning its Bendeka® oncology product, in which the patents found valid and infringed
• Neptune Generics v. Corcept Therapeutics – Defended Corcept against Neptune’s challenge to a patent covering its Korlym® drug product, in which the Patent Trial and Appeal Board (PTAB) found that Neptune failed to prove that any of the challenged claims were unpatentable
• Mallinckrodt Pharmaceuticals v. B. Braun Medical – Secured a favorable settlement for Mallinckrodt in Hatch-Waxman patent litigation concerning its Ofirmev® injectable acetaminophen product
• Merck Sharp & Dohme v. Warner Chilcott – Represented Merck in Hatch-Waxman patent litigation involving its NuvaRing® contraceptive product.*
• Janssen Pharmaceutica NV v. Mylan Labs – Represented Janssen Pharmaceutica (Johnson & Johnson) in Hatch-Waxman patent litigation concerning Dyloject®, an injectable nonsteroidal anti-inflammatory drug.*
• Stiefel Labs v. Perrigo Israel Pharms – Represented Stiefel Laboratories, a GSK company, in Hatch-Waxman patent litigation involving OLUX-E®, a topical corticosteroid for treating psoriasis and atopic dermatitis.*
• Celgene Corp. v. Fresenius Kabi – Represented Celgene in Hatch-Waxman patent litigation involving Istodax®, an injectable used to treat patients with T-cell lymphoma.*
• Advised Chardan Healthcare Acquisition 2, a special-purpose acquisition company, on patent aspects of its business combination with Renovacor, an early-stage biotechnology company developing AAV-based gene therapies for cardiovascular and central nervous system diseases resulting from BAG3 gene dysfunction
• Advised Siemens Healthineers, a medical technology company, on the patent portfolio aspects of its acquisition of Varian Medical Systems, a world leader in the field of cancer care that uses artificial intelligence, machine learning, and data analysis to improve cancer treatment

*Matter handled prior to joining Latham